These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 9351536)

  • 1. Pharmacoeconomics of haemophilia.
    Cooke J
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S41-4. PubMed ID: 9351536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
    Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
    Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylaxis in people with haemophilia.
    Coppola A; Franchini M; Tagliaferri A
    Thromb Haemost; 2009 Apr; 101(4):674-81. PubMed ID: 19350110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life assessment in clinical practice in haemophilia treatment.
    Gringeri A; Mantovani L; Mackensen SV
    Haemophilia; 2006 Jul; 12 Suppl 3():22-9. PubMed ID: 16683993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence-based medicine: can it be applied to stimulation of erythropoiesis for patients with malignancy?
    Rizzo JD
    Best Pract Res Clin Haematol; 2005; 18(3):439-48. PubMed ID: 15792918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacoeconomics.
    Ahuja J; Gupta M; Gupta AK; Kohli K
    Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomics.
    Sule NS; Nerurkar RP; Kamath SA
    J Assoc Physicians India; 2002 Aug; 50():1057-62. PubMed ID: 12421032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacoeconomics of acne treatment: where are we heading?
    Inglese MJ; Fleischer AB; Feldman SR; Balkrishnan R
    J Dermatolog Treat; 2008; 19(1):27-37. PubMed ID: 18273722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investing in hemophilia care: benefits and costs for patients and society.
    Scalone L
    Semin Hematol; 2008 Apr; 45(2 Suppl 1):S31-4. PubMed ID: 18544422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Health outcomes analysis and its applications].
    Carrera-Hueso FJ
    Rev Med Univ Navarra; 1997; 41(4):237-44. PubMed ID: 10420964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacoeconomics and immunotherapy.
    Berto P
    Eur Ann Allergy Clin Immunol; 2007; 39 Spec No():12-6. PubMed ID: 18924461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linking pharmacoeconomic analyses to results of systematic review and meta-analysis.
    Jordan HS; Lau J
    Expert Rev Pharmacoecon Outcomes Res; 2003 Aug; 3(4):441-8. PubMed ID: 19807454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haemophilia A: pharmacoeconomic review of prophylaxis treatment versus on-demand.
    Unim B; Veneziano MA; Boccia A; Ricciardi W; La Torre G
    ScientificWorldJournal; 2015; 2015():596164. PubMed ID: 25685844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacoeconomics in contemporary medicine].
    Czech M
    Pol Merkur Lekarski; 2004 May; 16 Suppl 1():16-9. PubMed ID: 15524007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addressing current challenges in haemophilia care: consensus recommendations of a European Interdisciplinary Working Group.
    Ludlam CA; Mannucci PM; Powderly WG;
    Haemophilia; 2005 Sep; 11(5):433-7. PubMed ID: 16128884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recommendations for postmarketing surveillance studies in haemophilia and other bleeding disorders.
    Lassila R; Rothschild C; De Moerloose P; Richards M; Perez R; Gajek H;
    Haemophilia; 2005 Jul; 11(4):353-9. PubMed ID: 16011587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
    Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P
    N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group.
    Nicholson A; Berger K; Bohn R; Carcao M; Fischer K; Gringeri A; Hoots K; Mantovani L; Schramm W; van Hout BA; Willan AR; Feldman BM
    Haemophilia; 2008 Jan; 14(1):127-32. PubMed ID: 18005148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.